TNFRSF4 and neoplasm: We demonstrate that pre-treatment with anti-CTLA4 antibodies provided optimal tumor control, while an alternate immunotherapy with anti-OX40, which targets recently-activated T cells, was optimal if delivered immediately following radiation therapy.